Q3 2025 Revenues of $246.0 million grew 6.7% compared to Q3 2024
Net Loss of $69.8 million
Adjusted EBITDA of $155.1 million increased 9.5% compared to Q3 2024 (Adjusted EBITDA Margin of 63.1% versus 61.5% in Q3 2024)
Claritev raises full-year 2025 revenue and Adjusted EBITDA guidance
November 7, 2025—Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2025.
